Eisai Co., Ltd. (TYO:4523)
Japan
· Delayed Price · Currency is JPY 3,999.00
+109.00 (2.80%)
May 13, 2025, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 216.14B JPY in the quarter ending December 31, 2024, with 21.63% growth. This brings the company's revenue in the last twelve months to 791.66B, up 5.63% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
791.66B
Revenue Growth
+5.63%
P/S Ratio
1.39
Revenue / Employee
71.53M
Employees
11,067
Market Cap
1,096.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
| Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
| Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
| Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
| Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 869.37B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 993.33B |
Eisai News
- 26 days ago - Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
- 27 days ago - Biogen/ Eisai win EU approval for Alzheimer’s therapy - Seeking Alpha
- 27 days ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 5 weeks ago - Japanese Stocks Rise With Market Focused on U.S. Trade News - Barron's
- 2 months ago - LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight - Benzinga
- 2 months ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 2 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 3 months ago - Q3 2025 Eisai Co Ltd Earnings Presentation Transcript - GuruFocus